Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134773) titled 'Fecal Resistance Gene-Guided Individualized Dual Therapy in Treatment-Naive Patients With Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial' on Oct. 20.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Peking University First Hospital
Condition:
Helicobacter pylori (H.pylori) infection
Intervention:
Dual regimen:Individualized dual regimen guided by fecal resistance test (Vonoprazan 20mg bid, combined with Clarithromycin 500mg bid, or Levofloxacin 500mg qd, or Amoxicillin 1000mg bid, for 14 days)..
Recruitment Status: Not Recruiting
Phase: N/A
Date of Firs...